Although HDAC inhibitors have negative/detrimental effects on immune cell viability and function, increasing evidence also supports a rationale to combine HDAC inhibitors with immunotherapy to obtain synergistic anti-tumor effects. Here, HDAC9 is linked to neoplasm.